Delivery Order SPE2DB20D2014-SPE2DB25FC73A
Award Date 8/13/25
Potential Completion Date 8/14/25
Potential Value $12K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $39,491.47 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at approximately $60.3K to AmerisourceBergen Drug Corp for RINVOQ ER 45 MG tablets (UU 28S) with an ultimate completion date of August 13, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ is a JAK inhibitor used to treat rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $21,494.79 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (UU 28s) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. RINVOQ ER is a prescription medication used to treat rheumatoid arthritis and other...
- The Defense Logistics Agency awarded a delivery order valued at $10,006.04 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 21, 2025, with completion expected by July 22, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other...
- The Defense Logistics Agency awarded a delivery order valued at $19,029.90 to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 30 mg tablets in quantities of 30 units. This is a firm fixed-price contract with no set-aside designation, competitively awarded to support federal medical procurement needs. The delivery order is scheduled for completion by August 4, 2025, with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. RINVOQ is...
- The Defense Logistics Agency awarded a $29,485.37 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-unit package) on July 30, 2025, with a completion date of July 31, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a JAK inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the Defense Logistics Agency's...
- The Defense Logistics Agency awarded a $12,446.64 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a prescription medication used to treat rheumatoid arthritis and...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $35,073.98 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 30, 2025, with performance completion due July 31, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 MG tablets (28-count unit dose packaging) on August 8, 2025, with an ultimate completion date of August 11, 2025. This competitively awarded, firm fixed-price delivery order has a ceiling value of $11,665.94 and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for RINVOQ ER 15 MG tablets in a quantity of 30 units, with a ceiling value of $26,170.68. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The order is expected to be completed by August 14, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....